Literature DB >> 1921448

Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro.

S N Yi1, J Wass, P Vincent, H Iland.   

Abstract

Mylabris, the dried body of the Chinese blister beetle, has been used as a Chinese medicinal for over 2000 years. Its active constituent, cantharidin, has antitumor properties and causes leukocytosis. Norcantharidin (NCTD), the demethylated form of cantharidin, is easier to synthesize and is less toxic. NCTD irreversibly reduced the clonogenic efficiency of parental and drug-resistant K562 sublines, with drug-resistant sublines showing greater susceptibility to NCTD than parental cells. NCTD inhibited DNA synthesis by blocking cells at the G2/M phase of the cell cycle. The data suggest that NCTD may be suitable in the treatment of drug-resistant leukemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1921448     DOI: 10.1016/0145-2126(91)90163-n

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

1.  Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction.

Authors:  Chung-Hsin Yeh; Yu-Yen Yang; Ya-Fang Huang; Kuan-Chih Chow; Ming-Feng Chen
Journal:  Chin J Integr Med       Date:  2012-08-31       Impact factor: 1.978

2.  Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells.

Authors:  Yue-Zu Fan; Jin-Ye Fu; Ze-Ming Zhao; Cun-Qiu Chen
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

3.  Cantharidins induce ER stress and a terminal unfolded protein response in OSCC.

Authors:  Y Xi; D M Garshott; A L Brownell; G H Yoo; H-S Lin; T L Freeburg; N G Yoo; R J Kaufman; M U Callaghan; A M Fribley
Journal:  J Dent Res       Date:  2014-11-25       Impact factor: 6.116

4.  Suppressions of Migration and Invasion by Cantharidin in TSGH-8301 Human Bladder Carcinoma Cells through the Inhibitions of Matrix Metalloproteinase-2/-9 Signaling.

Authors:  Yi-Ping Huang; Chien-Hang Ni; Chi-Cheng Lu; Jo-Hua Chiang; Jai-Sing Yang; Yang-Ching Ko; Jing-Pin Lin; Jehn-Hwa Kuo; Shu-Jen Chang; Jing-Gung Chung
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-27       Impact factor: 2.629

Review 5.  Norcantharidin, derivative of cantharidin, for cancer stem cells.

Authors:  Chen-Hsi Hsieh; K S Clifford Chao; Hui-Fen Liao; Yu-Jen Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-02       Impact factor: 2.629

6.  Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption.

Authors:  Yong-yan Bei; Xiao-yan Chen; Yang Liu; Jing-yu Xu; Wen-juan Wang; Zong-lin Gu; Kong-lang Xing; Ai-jun Zhu; Wei-liang Chen; Lin-seng Shi; Qin Wang; Xue-nong Zhang; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2012-04-03

7.  A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.

Authors:  Xin-Ping Li; Wei Jing; Jian-Jun Sun; Zhong-Yan Liu; Jing-Tao Zhang; Wei Sun; Wei Zhu; Yue-Zu Fan
Journal:  BMC Cancer       Date:  2015-07-19       Impact factor: 4.430

8.  Molecular biology of cantharidin in cancer cells.

Authors:  Rolf Rauh; Stefan Kahl; Herbert Boechzelt; Rudolf Bauer; Bernd Kaina; Thomas Efferth
Journal:  Chin Med       Date:  2007-07-04       Impact factor: 5.455

9.  Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.

Authors:  Jing-Tao Zhang; Wei Sun; Wen-Zhong Zhang; Chun-Yan Ge; Zhong-Yan Liu; Ze-Ming Zhao; Xing-Sui Lu; Yue-Zu Fan
Journal:  BMC Cancer       Date:  2014-03-15       Impact factor: 4.430

10.  Norcantharidin induced DU145 cell apoptosis through ROS-mediated mitochondrial dysfunction and energy depletion.

Authors:  Bo Shen; Pei-Jie He; Chun-Lin Shao
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.